These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18563070)

  • 21. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug interaction studies on new drug applications: current situations and regulatory views in Japan.
    Nagai N
    Drug Metab Pharmacokinet; 2010; 25(1):3-15. PubMed ID: 20208385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of recently approved 505(b)(2) new drug applications (2010-2012): role of clinical pharmacology.
    Agarwal S; Qiu W; Sahajwalla C
    J Clin Pharmacol; 2014 Dec; 54(12):1330-6. PubMed ID: 24958449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multimodality cardiovascular molecular imaging, part I.
    Sinusas AJ; Bengel F; Nahrendorf M; Epstein FH; Wu JC; Villanueva FS; Fayad ZA; Gropler RJ
    Circ Cardiovasc Imaging; 2008 Nov; 1(3):244-56. PubMed ID: 19808549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
    Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
    Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multimodality nanotracers for cardiovascular applications.
    Mulder WJ; Cormode DP; Hak S; Lobatto ME; Silvera S; Fayad ZA
    Nat Clin Pract Cardiovasc Med; 2008 Aug; 5 Suppl 2():S103-11. PubMed ID: 18641599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.
    Kiser JJ
    Curr Opin HIV AIDS; 2008 May; 3(3):330-41. PubMed ID: 19372987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing participation of women in early phase clinical trials approved by the FDA.
    Pinnow E; Sharma P; Parekh A; Gevorkian N; Uhl K
    Womens Health Issues; 2009; 19(2):89-93. PubMed ID: 19272558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
    Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
    Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiopharmaceuticals: molecular imaging using positron emission tomography.
    Antoni G; Långström B
    Handb Exp Pharmacol; 2008; (185 Pt 1):177-201. PubMed ID: 18626804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Results and prospects of development of neuropharmacology in the department of pharmacology of the Acad. S. V. Anichkov Research Institute of Experimental Medicine, USSR Academy of Medical Sciences].
    Borodkin IuS; Zavodskaia IS; Losev NA; Moreva EV; Sapronov NS
    Vestn Akad Med Nauk SSSR; 1990; (11):16-23. PubMed ID: 2284839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive structural, functional, and molecular imaging in drug development.
    Rudin M
    Curr Opin Chem Biol; 2009 Jun; 13(3):360-71. PubMed ID: 19447067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The quantity and quality of worldwide new drug introductions, 1982-2003.
    Grabowski HG; Wang YR
    Health Aff (Millwood); 2006; 25(2):452-60. PubMed ID: 16522586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of imaging methods to assess adiposity and metabolism.
    Heymsfield SB
    Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S76-82. PubMed ID: 19136995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.